Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Northwest Christmas
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 25, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 24, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 08, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
August 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 17, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 29, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 16, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 26, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
April 19, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 21, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 03, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 27, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
October 12, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 30, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 04, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
July 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
July 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
June 01, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 05, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
April 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
April 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
March 29, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.